CF
FULC icon

Corebridge Financial’s Fulcrum Therapeutics FULC Stock Holding History

Corebridge Financial’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-26,381
Closed -$76K – 1056
2025
Q1 		$76K Sell
26,381
-4,469
-14% -$16.4K ﹤0.01% 2580
2024
Q4 		$145K Sell
30,850
-2,329
-7% -$8.59K ﹤0.01% 2355
2024
Q3 		$118K Sell
33,179
-204
-0.6% -$1.51K ﹤0.01% 2525
2024
Q2 		$207K Buy
+33,383
New +$253K ﹤0.01% 2173

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Corebridge Financial's FULC Position: Q2 2025 in Review

Corebridge Financial sold out of Fulcrum Therapeutics (FULC) in Q2 2025, closing a stake of 26,381 shares — an estimated $76K sold.

Corebridge Financial first reported a position in FULC in Q2 2024 and held it in 4 quarters. The position peaked at $207K in Q2 2024. 122 funds tracked by Wall St. Rank hold FULC as of Q2 2025.

  • Corebridge Financial reported no remaining Fulcrum Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 26,381 Fulcrum Therapeutics shares in Q2 2025, an estimated $76K.
  • Corebridge Financial first reported a position in Fulcrum Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Fulcrum Therapeutics position peaked at $207K in Q2 2024.
  • 122 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.